News
Kiniksa Expects 2024 ARCALYST Net Product Revenue Of Between $360M-$380M; That Its Cash, Cash Equivalents, And Short-Term Investments Will Fund Its Current Operating Plan Into At Least 2027
28 Feb 24
News, Guidance
Kiniksa Pharmaceuticals Q4 EPS $0.35 Beats $(0.14) Estimate, Sales $83.39M Beat $72.02M Estimate
28 Feb 24
Earnings, News
Earnings Scheduled For February 28, 2024
28 Feb 24
Earnings
Earnings Outlook For Kiniksa Pharmaceuticals
27 Feb 24
Earnings
Press releases
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
16 Apr 24
Press Releases
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
2 Apr 24
Press Releases
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
28 Feb 24
Earnings, Press Releases
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
21 Feb 24
Press Releases